ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows

GLASGOW, Scotland, June 3, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD),...